Washington University School of Medicine in St. Louis scientists Michael S. Diamond, MD, PhD, (left) and Sean Whelan, PhD, lead a team working to minimize the risk of another devastating coronavirus pandemic by designing a vaccine that reduces sickness and death caused by all potentially deadly coronaviruses, including ones that have not yet affected people. The research is supported by an $8 million grant from the National Institute for Allergy and Infectious Diseases of the National Institutes of Health (NIH).
A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is on the path to becoming available in the U.S., Europe and Japan.
The world’s first nasal vaccine for COVID-19 was approved Tuesday, Sept. 6, in India for emergency use. The vaccine, called iNCOVACC, is based on technology licensed from Washington University in St. Louis and developed in collaboration with Bharat Biotech International Limited in India.
A biotechnology company launched to address lysosomal dysfunction in rare, genetically defined neurodegenerative diseases
A hyperspectral imaging company designing innovative solutions for analyzing 3D data
A woman-owned enterprise with a mission to help organizations improve the health and well-being of their employees, customers, and constituents by delivering evidence-based, easy to understand health information
Created products for clinical and research professionals to safely teach while advancing the standard of patient care
Will transform biomedical research and clinical practice by enabling precision medicine with personalized proteomics information
Develops and commercializes dual-use medical technologies to radically improve health outcomes for warfighters, veterans and civilians
Created a deluxe mobile hearing healthcare program, Amptify, that includes a daily interactive curriculum, expanded auditory training games, and a social network to imrpove listening skills